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Testicular germ cell tumour (TGCT) is the most common malignancy in men aged 15–45 years. A small deletion on the Y
chromosome known as ‘gr/gr’ was shown to be associated with a two-fold increased risk of TGCT, increasing to three-fold in cases
with a family history of TGCT. Additional deletions of the Y chromosome, known as AZFa, AZFb and AZFc, are described in patients
with infertility; however, complete deletions of these regions have not been identified in TGCT patients. We screened the Y
chromosome in a series of TGCT cases to evaluate if additional deletions of Y were implicated in TGCT susceptibility. Single copy Y
chromosome STS markers with an average inter-marker spacing of 128kb were examined in constitutional DNA of 271 index TGCT
patients. Three markers showed evidence of deletions, sY1291, indicative of ‘gr/gr’ (eight out of 271; 2.9%), Y-DAZ3 contained within
‘gr/gr’ (21 out of 271; 7.7%) and a single deletion of the marker G66152 was identified in one TGCT case. No other markers
demonstrated deletions. While several regions of the Y chromosome are known to be deleted and associated with infertility, our
study provides no evidence to suggest regions of Y deletion, other than ‘gr/gr’, are associated with susceptibility to TGCT in UK
patients.
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Testicular germ cell tumour (TGCT) is the most common cancer in
men aged 15–45 years. The worldwide incidence of the disease is
7.5 per 100000, but the rates vary considerably between countries
and racial and ethnic groups (Ferlay et al, 2004). The highest
incidence of the disease occurs in men of European descent and
the lowest in African and Asian groups (Ferlay et al, 2004). Risk
factors for TGCT include a family history of disease (Forman et al,
1992; Heimdal et al, 1996; Westergaard et al, 1996; Sonneveld
et al, 1999; Hemminki and Li, 2004), a previously diagnosed germ
cell tumour (Osterlind et al, 1991; Wanderas et al, 1997), a history
of undescended testis (UDT) (Brown et al, 1987; Swerdlow et al,
1997), infertility (Petersen et al, 1998; Moller and Skakkebaek,
1999; Jacobsen et al, 2001; Richiardi et al, 2004), atrophy (Harland
et al, 1998) and gonadal dysgenesis (Verp and Simpson, 1987).
Family history is one of the strongest of the underlying risk
factors. Multiple studies have documented that brothers and
fathers of patients with TGCT have a 8–12-fold and 4–6-fold risk,
respectively (Forman et al, 1992; Heimdal et al, 1996; Westergaard
et al, 1996; Sonneveld et al, 1999; Hemminki and Li, 2004). These
relative risks are higher than for most other cancer types, which
rarely exceed 4 (Hemminki et al, 2001) and suggest that there is
a substantial contribution to the disease risk from underlying
susceptibility genes.
Despite the high familial risk, the underlying genetic suscept-
ibility to the TGCT remains unclear. A recent genome-wide linkage
search on 237 TGCT pedigrees, the largest series of TGCT families
examined to date, identified several ‘regions of interest’ on
chromosomes 2p33, 3p12, 3q26, 12q13–q21, 18q21–q23 and
Xq27. Each region demonstrated a HLOD score of greater than 1
but not exceeding 2. The study showed that susceptibility to TGCT
could not be accounted for by a single major gene or even two
major genes (like for example BRCA1 or BRCA2 in breast cancer)
and was more likely to be due to several genes with modest or
small effects on risk (Crockford et al, 2006).
Recently, we and others examined the ‘gr/gr’ deletion on the Y
chromosome in a series of 4441 TGCT cases and control males and
showed that this 1.6Mb deletion was associated with an two-fold
increased risk of TGCT, increasing to three-fold in patients with a
family history of TGCT, suggesting that this deletion is a rare, low
penetrance allele conferring susceptibility to TGCT (Nathanson
et al, 2005).
The ‘male-specific region’ (MSY) of the Y chromosome contains
an ampliconic region made up of eight massive palindromes,
which show greater that 99.9% homology. Large deletions of the
ampliconic region of the Y known as AZFa, -b and -c (MIM
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s415000) have been described in patients with infertility. These
deletions generally remove all copies of a specific gene family
resulting in complete infertility (Vogt et al, 1996; Kuroda-
Kawaguchi et al, 2001). The smaller ‘gr/gr’ deletion, which lies
within the AZFc region, removes some but not all of the testis-
specific Y gene copies, and transmission of this deletion from
father to son has been described (Repping et al, 2003). Several
studies have examined constitutional DNA from TGCT patients for
deletions of the AZF regions on the Y chromosome. A total of 457
TGCT patients were examined and no deletions were identified in
the AZF regions (Frydelund-Larsen et al, 2003; Lutke Holzik et al,
2005; Bor et al, 2006). However, the STS markers used for the
analysis would not detect the ‘gr/gr’ deletion. Two further studies
have examined the AZF regions in a series of TGCT patients in
constitutional and tumour material, reporting a high frequency of
deletions in normal and tumour samples. In a series of 17 Finnish
men, 76.4% showed deletions of between one and eight STS
markers and in 40 TGCT cases from Norway and Argentina,
25% of cases showed a deletion of at least one STS marker.
Interestingly, none of these deletions showed a contiguous pattern
with more than two STS markers deleted. Furthermore, the
deletions or absence of an STS marker in constitutional DNA was
shown to be present in the corresponding tumour material of
cases. It is difficult, therefore, to conclude if these are real Y
microdeletions or if the deletions are due to some form of
mosaicism as the authors suggest (Bianchi et al, 2002, 2006;
Richard et al, 2004).
We considered that additional as yet unidentified deletions of
the Y chromosome, particularly in the ampliconic region of MSY,
could also be implicated in TGCT susceptibility and therefore
examined the Y chromosome in the constitutional DNA of a series
of TGCT cases with a fine STS marker map to determine if
additional regions of deletion could be implicated in the disease.
METHODS
Testicular germ cell tumour patient samples were collected from
UK oncology centres as part of a study into genetic susceptibility
to TGCT. Patients donated samples and medical information with
full informed consent and with local or national ethical review
board approval. Information on clinical status, including type of
TGCT, age of diagnosis, presence of UDT and laterality of disease,
was confirmed by reviewing histological reports and clinical notes.
DNA was extracted from whole blood using standard techniques.
Samples were allocated to three analysis groups: ‘family history’,
patients with TGCT and another family member affected with
TGCT; ‘sporadic’, TGCT patients with no family history of disease
and ‘UDT’, TGCT cases without a family history of TGCT but with
a family history of UDT. Control male DNA samples were
purchased from the European Collection of Cell Cultures (ECACC).
All control samples and TGCT samples were from white UK males;
however, cases and controls were not age matched.
Markers were selected from the NCBI database (http://
www.ncbi.nlm.nih.gov/). A marker was selected if it existed in a
single copy on the Y chromosome sequence and if there was
specific sequence map location (Homo sapiens build 35.1). A total
192 Y chromosome STS markers were selected to be evenly spaced
from the p to q arm. All samples were checked for the presence of
the SRY gene (genBank accession number¼G38356).
The STS markers were amplified in a single-plex reaction
containing 25ng genomic DNA using standard conditions.
Polymerase chain reaction products were run on 2% agarose gels
and visualised by staining with ethidium bromide. Samples were
scored as positive if a PCR fragment at the correct size was seen on
the gel, and negative if no PCR product was seen. For all markers
other than sY1291 and Y-DAZ3, negative samples were repeated in
a single-plex reaction and in a multiplex reaction with the SRY
gene acting as a positive control. If samples remained negative, the
primers for the STS marker were redesigned so that the new
primer sites flanked the existing STS. The newly designed primer
pairs were retested on previously negative samples in both single-
plex and multiplex reactions ensuring that the deletion was not
due to a polymorphism within the original primer site. Only if the
sample remained negative after amplification of the modified
primer pairs was the sample scored as deleted. For sY1291 and Y-
DAZ3, the repetitive nature of the Y chromosome sequence in
these regions prevented the design of flanking primers that only
amplified a single copy of the Y sequence. Deletions of sY1291
were confirmed by a multiplex reaction as previously described
(Nathanson et al, 2005). Deletions of Y-DAZ3 were confirmed by a
single-plex reaction and two multiplex reactions, one with SRY
acting as the positive control and one with sY1240 as a positive
control.
RESULTS
Patient series
Two hundred and seventy-one samples were examined in this
study, of which 167 cases had TGCT and a family history of disease
(family history group), 96 patients had TGCT and no family
history (sporadic group) and eight cases had TGCT and a family
history of UDT (UDT group) (Table 1a). All patients had TGCT
except for five, who were diagnosed with extragonadal germ cell
tumours. Eighteen patients had bilateral disease, 12 in the family
history group and six in the sporadic group. The pedigree
structures, histologies and age of diagnosis for the series is shown
in Tables 1a and b.
Y STS marker map
The average marker spacing of the single copy Y STS markers is
128kb. The list of the STS markers used in the analysis can be
found in the Supplementary Table. Four regions had inter-marker
distances of greater than 1Mb (largest 1.55Mb). These regions
were at 4.1Mb (DYS253) – 5.3Mb (sY1240); 11.2Mb (sY1200) –
12.2Mb (G65937), 23.8Mb (sY1291) – 25.2Mb (Y-DAZ3) and
25.2Mb (Y-DAZ3) – 26.7Mb (sY1201) along the Y chromosome
sequence. Single copy STS markers could not be identified within
Table 1a Characteristics of TGCT samples used in study – pedigree
structure
Group Family structure
Number of
index cases per
family type
Total
number of
TGCT cases
Family history 167
Sib pair 75
Sib trio 2
Father/son pair 28
Cousin pair 25
Large 43 affected
cases
11
Uncle nephew pair 18
Grandfather/
grandson
4
Twins (MZ) 4
Sporadic 96
UDT 8
Total 271
TGCT¼testicular germ cell tumour; UDT¼undescended testis.
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sthese regions from the public databases. An additional seven
regions had inter-marker distances of greater than 0.5Mb.
Seven STS markers initially gave negative results across multiple
samples. Each of these STS had the primers redesigned so that the
new primer pair flanked the old pair. After amplification with the
new primers, all samples, except in one case as reported below,
demonstrated a PCR product of the correct size indicating that the
STS was not truly deleted and that the original nonamplification
was likely to be due to a polymorphism in the original primer sites.
STS marker deletion analysis
All samples were investigated for the presence of the SRY gene and
all samples were positive for this marker. One hundred and ninety-
two single copy STS Y markers were examined in all samples.
One STS, G66152, showed a single deletion in one TGCT case.
The sample remained negative in multiplex analysis and also once
the primers were redesigned flanking the original primer sites.
The patient had a right-sided non-seminoma at age 31 years and
no family history of TGCT. He also had an operation for an
undescended testis on the left side at age 8 years. The patient is
considered ‘fertile’ as he has one child. There was no DNA
available from other family members to determine if this deletion
was shared with other male relatives.
Two STS markers sY1291 (GenBank Accession Number G72340)
and Y-DAZ3 (G73170) were deleted in multiple samples. sY1291 is
the marker used to indicate a gr/gr deletion and eight samples
(Table 2) demonstrated a deletion in this region. The frequency of
gr/gr in this series was 2.9%. All samples demonstrating a gr/gr
deletion have been reported previously in Nathanson et al (2005).
Twenty-one of 271 (7.7%) TGCT cases showed deletions in
Y-DAZ3 (Table 2). Examination of this region in a series of 399
control male samples from the ECACC showed 30 deletions
(7.5%) (P¼1.0, Fishers exact test). Only three TGCT cases and two
controls demonstrated deletions for both sY1291 and Y-DAZ3
(Table 2). Owing to the repetitive nature of the Y chromosome
sequence in this region, neither of these STS could be redesigned
with flanking primers and ensure that the STS remained single
copy. However, the analysis in both single-plex and multiplex
reactions was repeated at least three times and remained negative.
Of the 21 TGCT cases with Y-DAZ3 deletions, 10 cases had a
seminoma (46%), seven cases had a non-seminoma (33%) and four
(19%) had a mixed histology tumour. Two cases, one with a family
history and one without, had bilateral disease. The average age of
diagnosis of the first tumour for the group was 29.25 years.
Fertility status was unknown, but only five of 21 (24%) cases
reported having children.
In TGCT cases with a ‘gr/gr’ deletion as characterised by a
negative result at sY1291, six cases had a seminoma (75%), one a
non-seminoma (12.5%) and one case had a mixed histology
tumour (12.5%). The ‘gr/gr’ deletion has previously been shown to
be more strongly associated with seminoma (Nathanson et al,
2005). Four of eight cases reported having children.
Markers spanning the AZFa, AZFb and AZFc regions of the Y
chromosome, frequently deleted in patients with infertility, were
examined by markers spanning and flanking these regions. The
AZFa region was evaluated by 15 single copy STS markers. The
AZFb and AZFc regions, which exhibit a degree of overlap, were
evaluated with 46 single copy STS (Supplementary Table). No
deletions were demonstrated in either the AZFa or AZFb region.
The AZFc region contains the 1.6Mb gr/gr region and the only
deletions observed in this series were in the ‘gr/gr’ region, and
there was no evidence of the larger AZFc deletion.
DISCUSSION
Having previously identified an association between the Y
chromosome ‘gr/gr’ deletion and TGCT, a physical analysis of
the Y chromosome was conducted to determine if additional
regions of the Y chromosome are implicated in TGCT suscept-
ibility, focusing particularly on the MSY region. Our analysis
showed that other than the ‘gr/gr’ deletion, no other deletions of Y
are likely to be associated with TGCT risk. Although it is possible
Table 1b Characteristics of TGCT samples used in study – histology and age of diagnosis (of first tumour)
Seminoma Non-seminoma Mixed histology Unknown
All histology
(and unknown histology)
Group
Number of
cases
Age of
diagnosis
Number of
cases
Age of
diagnosis
Number of
cases
Age of
diagnosis
Number of
cases
Age of
diagnosis
Number of
cases
Age of
diagnosis
Family history 81 (0.52) 37.22 65 (0.41) 28.14 11 (0.07) 34.54 10 29.22 167 33.08
Sporadic 38 (0.40) 35.5 42 (0.45) 30.23 14 (0.15) 31.43 2 47.5 96 32.85
UDT 6 (0.86) 28.16 0 (0.00) — 1 (0.14) 45 1 42 8 32
Total 125 36.26 107 28.97 26 33.26 13 33.97 271 32.97
TGCT¼testicular germ cell tumour; UDT¼undescended testis.
Table 2 Deletions in sY1291 and Y-DAZ3
Group
Family
history OR Sporadic OR UDT OR
All TGCT
cases OR Controls
sY1291 (gr/gr) 4/167 (0.024) 1.61 (0.33, 6.87) 4/96 (0.04) 2.85 (0.58, 12.26) 0/8 0.0 (0.0, 34.6) 8/271 (0.029) 1.99 (0.60, 7.04) 6/399 (0.015)
Y-DAZ3 12/167 (0.072) 0.95 (0.43, 1.98) 9/96 (0.094) 1.27 (0.51, 2.87) 0/8 0.0 (0.0, 6.08) 21/271 (0.077) 1.03 (0.55, 1.91) 30/399 (0.075)
Both sY1291 and
Y-DAZ3 deletion
2/167 (0.012) 2.41 (0.17, 33.4) 1/96 (0.010) 2.09 (0.04, 40.5) 0/8 0.0 (0.0, 106.5) 3/271 (0.011) 2.22 (0.25, 26.73) 2/399 (0.005)
Y-DAZ3 deletion
only
10/167 (0.060) 0.84 (0.36, 1.84) 8/96 (0.081) 1.20 (0.46, 2.83) 0/8 0.0 (0.0, 6.56) 18/271 (0.079) 0.94 (0.48, 1.81) 28/399 (0.103)
The table reports the number of samples showing the deletion compared to the number tested (and the proportion) plus the odds ratio (OR) for the comparison to the
controls (and 95% confidence interval) for the family history positive group and the family history negative group.
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sthat we may have missed small regions of deletions, particularly
in those few regions where the inter-marker spacing exceeds 1Mb,
none of our inter-marker distances exceeds that of deletions
previously described for the Y, including the ‘gr/gr deletion.
Previous studies of Y chromosome deletions in TGCT has
focused on the AZF deletion regions initially identified in patients
with infertility. Many of the markers used in previous studies have
also been utilised for this study. Our study differs from previous
studies in that we examined these regions in more detail by using a
higher density of markers. Similar to the previous studies in
Danish and Norwegian TGCT patients (Frydelund-Larsen et al,
2003; Lutke Holzik et al, 2005; Bor et al, 2006), no large contiguous
deletions were demonstrated for any sample in this series in the
AZF regions. We did not see the rate of noncontiguous deletions in
the AZF regions demonstrated previously for Finnish patients and
Argentinean TGCT patients (Bianchi et al, 2002, 2006; Richard
et al, 2004), suggesting that there is either a difference in the rate
of deletion between these populations or that there is some
methodological issue giving rise to nonamplification of a PCR
product rather that a true deletion of the Y chromosome DNA in
these studies. None of the previous studies of the AZF regions and
TGCT used STSs that would have detected the ‘gr/gr’ deletion.
We took considerable care to confirm all negative results.
Samples that initially showed a negative PCR reaction were
repeated in both a single-plex and a multiplex reaction, with SRY
as the positive control. If the sample remained negative in these
reactions, we redesigned the primer sites to flank the original
primer, thus eliminating the possibility of a polymorphism in the
primer site causing the nonamplification of the fragment. Only
for sY1291 and Y-DAZ3 was this procedure not possible due to the
degree of sequence identity in these regions with other Y regions.
However, these results were repeated on numerous occasions (at
least three times) in multiplex analyses and remained negative. We
are therefore confident that where a fragment failed to amplify that
it represented a true deletion on the Y chromosome DNA at that
position. The patient series in this study is large, well characterised
and includes patients both with and without a family history of
disease. All patients were white Caucasian males from the UK
and the series is representative of the ethnic group with one of
the highest incidences of TGCT. The patient series may not be
sufficiently large to detect very rare deletion variants, however
these rare variants would have little impact on overall suscept-
ibility to TGCT.
Eight of the patient series showed deletions of the ‘gr/gr’ region
as characterised by the absence of the marker sY1291. All patients
in the present study with ‘gr/gr’ have been reported previously as
part of a much larger series (Nathanson et al, 2005). The ‘gr/gr’
deletion as detected by the absence of the marker sY1291 can be
generated by a number of different Y rearrangements (Figure 1).
We identified three TGCT patients and two control patients with
deletions of both sY1291 and Y-DAZ3, which might suggest that
these variants arose via the r1/r4 mechanism (Figure 1). All other
‘gr/gr’ deletions did not have an accompanying deletion of Y-
DAZ3, which could implicate that these have arisen via the g1/g2
or r1/r3 mechanism (Figure 1). This observation suggests that
further characterisation of the ‘gr/gr’ deletion region is needed in
TGCT and this may provide information on the genes in this
region that are critical for TGCT susceptibility.
We observed that the frequency of Y-DAZ3 deletions alone was
similar among cases and controls. Both the patient data set and
the control series were all white Caucasian males from the UK.
The control series, while not collected in a formal case–control
fashion, would be expected to match the ethnic background of the
case series. This suggests that the deletion at Y-DAZ3 is a neutral
polymorphism in this population and not implicated in suscept-
ibility to TGCT. Analysis of SNV variants and the Y-DAZ3 marker
have suggested that deletions of DAZ3/4 are associated with Y
haplogroup N, which is common among Northern Europeans
(Fernandes et al, 2004). It is unknown if the Y-DAZ3 deletion
exists on the same Y haplotype among this series, as Y
chromosome haplotyping was not performed as part of this study.
A single sample demonstrated a deletion at the STS marker
G66152, both the flanking STS markers, sY1252 (196kb away) and
sY1253 (51kb away), were positive. As there are no genes
identified in this region, it is unlikely that the small deletion is
involved in pathogenesis of TGCT.
We have previously shown that the ‘gr/gr’ deletion is associated
with a two-fold risk of TGCT increasing to three-fold in TGCT
cases with a family history of disease. We evaluated the Y
chromosome with a dense marker map and no significant
additional deletion regions of the Y chromosome were detected.
Excluding the possibility of small deletions existing between
the STS markers used or very rare deletions of Y that may
not have been detected in this series, the study showed that other
than the previously characterised ‘gr/gr’ deletion, Y chromosome
deletions do not make a significant contribution to TGCT
susceptibility.
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